Activities of new beta-lactam antibiotics against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.
The in vitro activities of gentamicin, tobramycin, amikacin, azlocillin, carbenicillin, mezlocillin, piperacillin, ticarcillin, cefotaxime, ceftizoxime, cefoperazone, cefsulodin, moxalactam, ceftazidime, ceftriaxone, and N-formimidoyl thienamycin were measured against 62 isolates of Pseudomonas aeruginosa obtained from patients with cystic fibrosis. Ceftazidime and N-formimidoyl thienamycin were the most active of these agents.
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002228:Carbenicillin / Q000494:pharmacology; D002438:Cefoperazone; D002439:Cefotaxime / Q000494:pharmacology; D002442:Ceftazidime; D002511:Cephalosporins / Q000494:pharmacology; D003550:Cystic Fibrosis / Q000382:microbiology*; D015378:Imipenem; D010406:Penicillins / Q000494:pharmacology; D010878:Piperacillin; D011552:Pseudomonas Infections / Q000382:microbiology*; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000302:isolation & purification; D047090:beta-Lactams / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D010406:Penicillins; D047090:beta-Lactams; D015378:Imipenem; D002438:Cefoperazone; D002442:Ceftazidime; D002228:Carbenicillin; D002439:Cefotaxime; D010878:Piperacillin